Clinical OMICS

SEP-OCT 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 8 of 51 September/October 2018 Clinical OMICs 7 population genome projects in Europe, the United States, and Asia. It is the only technology proven for real-time gene discovery and diagnostics using hundreds of thousands of whole genomes. GOR is the emerging global standard architecture for turning genomic data into better health and medicine. Exploiting the natural structure of the genome itself, GOR and its integrated applications make it possible to query your own sequence data and all major global reference sets at unrivalled efficiency, scale, and speed—for one patient, across an institution or healthcare system, or between global reach teams and collaborators—securely in the cloud and online. Whether you are delivering healthcare or managing a worldwide clinical trial, WuXi NextCODE provides unique capabilities for deriving the insights you need from all of your data. Statistical Machine Learning and Best-in-Class Artificial Intelligence WuXi NextCODE also provides integrated, leading-edge bioinformatics and AI for: • Faster and more efficient drug target discovery • Lower-cost and more successful clinical trials • Drug repurposing or drug candidate salvage • Optimization of drug design through retrosynthesis analysis • Calculating appropriate reimbursement We use advanced statistical machine learning and AI in combination with our unparalleled GOR data analysis platform. (Figure 2) Thanks to our extensive experience and powerful analytics, we can draw insights from the biggest databases down to relatively small sets of just a few dozen samples. Those insights include finding "causal" driver genes and elucidating molecular signaling networks. In past partnerships, we've been able to uncover novel genes that appear to be drivers in cancer, cardiovascular disease, and a metabolic syndrome associated with several rare diseases. 1 Formalin-Fixed, Paraffin-Embedded (FFPE) Sample Analysis Formalin-fixed, paraffin-embedded (FFPE) tissue samples are plentiful but not easy to use. It is difficult to isolate high-quality DNA from them. But there is finally an answer to this problem. WuXi NextCODE has developed a proprietary, breakthrough nucleic acid extraction methodology, SeqPlus, that delivers maximum value for FFPE sequencing with coverage comparable to that achieved with fresh frozen samples. The new, gentler SeqPlus method more efficiently extracts fragments of higher molecular weight than traditional methods, while producing results that are close to those obtained with fresh frozen samples at comparable sequencing levels. We recently presented results from a study of more than 1,000 samples with this approach—the largest report on whole-genome sequencing of FFPE samples to date—as a poster at the 2018 meeting of the American Association for Cancer Research (AACR). 2 Our assay can provide robust results from archival tissue biobank samples, routine clinical processing of samples for clinical trial recruitment, or tissue sections as part of normal clinical diagnostic workflows. Individually, or wrapped together in a single package, WuXi NextCODE's services are unparalleled. They give groups at the leading edge of genomics the competitive advantage they need to stay ahead. References 1. Yu P, Wilhelm K, Dubrac A, et al. FGF-Dependent Metabolic Control of Vascular Development. Nature 2017 May 11: 545 (7653): 224-228. https://www.ncbi.nlm. 2. Bailey ST, Lund J, Wang, H, et al. 2018. Abstract 427: High-Quality Whole Genome Sequencing of FFPE Samples, American Association for Cancer Research (AACR). Figure 2. Our advanced analytical workflow To learn more about the WuXi NextCODE difference, contact

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - SEP-OCT 2018